Articles by Patrick Clinton - Pharmaceutical Executive


Articles by Patrick Clinton

Patient Centric

Five years ago, in the race to deliver Gleevec, Novartis leaders glimpsed what a pharma company could be. Today, across the company, theyre putting that experience to work.
Nov 1, 2004

It's a truism among pharmaceutical scientists that you can spend a whole career without working on a compound that goes on to become a successful product. On the executive side, you can devote a career to products that advance medicine incrementally, but never touch a true breakthrough—a drug that fundamentally changes way a disease is treated or companies do business. In an industry devoted to innovation, hardly anyone gets to experience revolutionary innovation.

Struggling to Take One Step Forward

Nov 1, 2004

Reeve had done something that many of us who communicate about health issues try in vain to accomplish.

Pharma's Most Important Product

Oct 1, 2004

In the real world, progress doesn’t result in fewer complaints. It leads to complaining about better things.

Under Construction

Oct 1, 2004

Kos Pharmaceuticals was first to market with a product to raise HDL cholesterol, and it wants to join pharma's billion-dollar club by 2007. Big plan. Here's how it's going.

Hire Expectations

The challenge of recruiting -- and how top companies are meeting it.
Jun 1, 2004

What are the industry's current hiring needs? What functions are most challenging to retain? How do misconceptions about working in pharma affect recruiting? These were some of the questions raised at an exclusive roundtable on pharma industry recruiting, co-sponsored by Pharmaceutical Executive and the New York Times Job Market.

Partners in Learning

These days, when pharma wants training, it goes to college.
May 1, 2004

College isn't just for students anymore. It's for companies too. Over the past decade, institutions of higher education have increasingly found that some of their most important stakeholders are their students' employers—and that they can extend their reach and influence by responding to the needs of local and regional business.

Twin Pillars

After a banner year, Roche looks ahead. What does it see? Drugs and diagnostics transforming medicine (and no mergers).
Mar 1, 2004

At the sprawling Roche Pharmaceuticals campus in Nutley, New Jersey, the US headquarters of the Swiss-based company, dominating the lobby of the main building stands a statue of a winged horse-white, alert, poised for flight.

Nothing Is Automatic

FDA Commissioner Mark McClellan on reimportation, risk, pricing, DTC, and his first year in office.
Jan 1, 2004

When Mark B. McClellan took office as the 18th commissioner of the Food and Drug Administration in November 2002, he came with a fascinating set of assets and liabilities. On the one hand, he had never run a regulatory agency, or indeed even worked for one. On the other, he was both a physician and an economist and had taken a leading role in US healthcare policy. (At one point, the biggest question about his candidacy was whether President Bush could spare him from the Council of Economic Advisors.) He had never worked for a pharma company-which meant he could pass Ted Kennedy's litmus test for confirmation-and he was unproven as a manager. But his understanding of the costs and benefits of healthcare was likely to be a real plus as the country grappled with the emerging issue of drug prices.

From Good to Great, Act Two

In 1974, Abbott Labs underwent a transformation. Can CEO Miles White make it happen again?
Dec 1, 2003

In his best-selling 2001 business book, Good to Great, consultant Jim Collins set out to discover what made some companies so much more successful than others. He researched more than 1,400 corporations, looking for examples of dramatic long-term improvements.


Click here